Translation. Region: Russian Federal
Source: Peter the Great St Petersburg Polytechnic University – Peter the Great St Petersburg Polytechnic University –
Polytechnic University received a grant from the Ministry of Education and Science for the development of scientific and technological infrastructure and technologies in the field of nuclear medicine, nanomedicine and hadron therapy, including the development of high-tech and radiopharmaceutical drugs.
The Polytechnic University has won the competitive selection for the provision of grants in the form of subsidies from the federal budget for the implementation of individual activities of the Federal Scientific and Technical Program for the Development of Synchrotron and Neutron Research and Research Infrastructure for the Period up to 2030 and Beyond. The grant is aimed at developing scientific and technological infrastructure and technologies in the field of nuclear medicine, nanomedicine and hadron therapy, including the development of high-tech and radiopharmaceutical drugs (RPhLD).
A group of scientists from SPbPU, headed by the director of the Institute of Biomedical Systems and Biotechnology Andrey Vasin, together with the scientific team of the Department of Molecular and Radiation Biophysics of the National Research Center “Kurchatov Institute” – PNPI, presented a research program for the competition dedicated to the development of new technologies for the encapsulation and delivery of radionuclides for the diagnosis and therapy of malignant neoplasms.
Currently, in Russia there are practically no original modern technological developments in the field of encapsulation of various radionuclides of therapeutic action, which can be further used to create new RFLPs to combat socially significant diseases, primarily malignant neoplasms. We plan to develop methods for obtaining hybrid nanocarriers for radionuclides and methods for encapsulating radioactive isotopes of radium-224 and iodine-125 in them by the end of 2025. And in the next two years, preclinical studies of the safety of the RFLPs being developed will be conducted and the effectiveness of their use for the treatment of malignant neoplasms in vivo will be studied, – noted Andrey Vasin.
There are also plans to implement an additional professional development program, “Modern methods of delivering radionuclides for the diagnosis and treatment of malignant neoplasms,” which will allow training personnel for the industry.
We are grateful to the Ministry of Science and Higher Education of the Russian Federation for supporting our project, which has quite a serious groundwork and an excellent team of researchers, including many young scientists. The funds received will also be used to modernize the equipment needed to conduct research in the field of developing RFLP drugs. Preventive maintenance of individual systems of the isochronous cyclotron MGC-20, which is used to produce radioactive isotopes to obtain RFLP, is planned. The plans include equipping areas for quality control of “cold” hybrid nanocarriers and isotopes based on the scientific divisions of the Institute of Biomedical Systems and Biotechnology, – commented the curator of the project, Vice-Rector for Research at SPbPU Yuri Fomin.
The project is being implemented jointly with the scientific team of the Department of Molecular and Radiation Biophysics of the National Research Center “Kurchatov Institute” – PNPI, which has a research infrastructure for the development and conduct of preclinical studies of radiopharmaceutical drugs. The project will be implemented during 2025-2027, the total funding will be 231 million rubles, including 21 million rubles of the organization’s own funds.
Please note: This information is raw content directly from the source of the information. It is exactly what the source states and does not reflect the position of MIL-OSI or its clients.